HDL functionality in familial hypercholesterolemia: effects of treatment modalities and pharmacological interventions

Shiva Ganjali, Amir Abbas Momtazi-Borojeni, Maciej Banach, Petri T. Kovanen, Antonio M. Gotto, Amirhossein Sahebkar

Research output: Contribution to journalReview article

12 Scopus citations

Abstract

Recent studies have demonstrated that assessment of high-density lipoprotein (HDL) functionality indices, instead of HDL cholesterol measurement, is a more robust tool for the evaluation of the functional status of HDL and cardiovascular risk. There are qualitative abnormalities of HDL particles in familial hypercholesterolemia (FH) patients that might represent potential therapeutic targets. Despite the potential promise of optimizing HDL functionality for the treatment of FH, there has been no prior comprehensive review focusing on the impact of different lipid-modifying therapies on HDL functionality in FH patients. In the present review, we aim to fulfill this gap and provide a concise summary on the impact of different lipid-modifying therapies on HDL functionality in FH.

Original languageEnglish (US)
Pages (from-to)171-180
Number of pages10
JournalDrug Discovery Today
Volume23
Issue number1
DOIs
StatePublished - Jan 2018

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'HDL functionality in familial hypercholesterolemia: effects of treatment modalities and pharmacological interventions'. Together they form a unique fingerprint.

Cite this